AstraZeneca Pharma India gains on regulator nod to import lung cancer drug
10/03/2025 07:52
** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month ** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution ** Drug is used to treat patients with a certain type of lung cancer ** Shares trading above 50-, 100-, 200-day moving avg ** ASTR up 2.2% YTD, after gaining 32% in 2024 (Reporting by Aleef Jahan in Bengaluru) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan